Planned system outage: A number of IT systems will be temporarily unavailable on 7 March 2026 from 10am–6pm AEDT due to scheduled maintenance. 

Full details

Planned library system outage: Access to library e-resources - including all e-books and e-journals - will be impacted by a system upgrade on Wednesday, 18 February 2026 from 8AM - 12PM AEDT / 10AM - 2PM NZDT.

Further information

The college will be closed from 2pm (AEDT) on Wednesday 24 December 2025 until Monday 5 January 2026. We wish you a happy and safe festive period.

MyPortfolio is now available via https://myportfolio.anzca.edu.au/. Please contact the ANZCA Training team at [email protected] if you have any queries or require assistance.

Understanding MRGPRX2-dependant, life-threatening anaphylaxis during anaesthesia: towards prediction and prevention.

Project Grant

In the vast majority of individuals anaesthetic drugs are effective and safe, but in rare cases they can produce severe life-threatening reactions. It is well-known that this severe allergy-like reaction, anaphylaxis, can cause circulatory failure during surgery, with potentially fatal consequences. Also well-known is that in anaphylactic reactions, the body generates the IgE antibody that interacts with the allergic substance, to stimulate mast immune cells which then release chemicals such as histamine to produce the severe symptoms of anaphylaxis.

However, although this IgE mechanism is important to some drug allergies, it does not explain all cases. Excitingly, a new mechanism has been revealed whereby certain drugs, such as rocuronium, can directly stimulate the MRGPRX2 receptor protein on the surface of mast cells, leading to their activation. Despite this advance, key questions remain: why are only some people affected? Could we identify individuals who are likely to suffer these reactions, and protect them from potentially devastating consequences?

Following the team’s previous work identifying polymorphisms in MRGPRX2, this study aimed to:

  • determine if polymorphisms in the MRGPRX2 gene, as identified in an existing cohort, underlie heightened sensitivity to NMBAs such as rocuronium
  • in human mast cells, characterise the intracellular signalling pathways initiated by different MRGPRX2 agonists that either do or do not lead to mast cell degranulation
  • grow mast cells from the peripheral blood of drug-sensitive MRGPRX2 polymorphic individuals to validate findings from the genetic and functional studies above.

Dr Brenton Sanderson, Westmead Hospital and Macquarie University, NSW
Professor Enrico Coiera, Macquarie University, NSW
Dr Jeremy Field, Westmead Hospital, NSW
Professor Erica Wood, Monash Univeristy, Melbourne, Vic
Dr Lise Estcourt, John Radcliffe Hospital, Oxford UK

The project was awarded $A130,244 including scholarship through the ANZCA research grants program in 2020.

The study was unable to demonstrate that the polymorphisms led to changes in MRGPRX2 function, in keeping with other studies that similarly failed to correlate MRGPRX2 polymorphisms to enhanced receptor activity. Thus, markers alternative to MRGPRX2 polymorphisms are needed to help predict susceptible individuals. These might include serum factors or the expression of other MRGPRX2 regulating proteins in human mast cells.

The team also discovered and characterised new endogenous and exogenous agonists of MRGPRX2; knowledge that will help better characterise the broader role of MRGPRX2 and potentially help identify biomarkers of MRGPRX2 activity, that could indeed be used to help identify patients with increased risk to perioperative drugs.

The study has led to three publications manuscripts that broaden understanding of MRGPRX2- induced mast cell activation; provide evidence for treatment options; and propose novel approaches to better define the factors contributing to rare but devastating drug -induced anaphylaxis. Many of the tools developed during the project will play important roles in ongoing future work.

Sanderson, B., Coiera, E., Asrianti, L., Field, J., Estcourt, L. J., & Wood, E. M. How well does your massive transfusion protocol perform? A scoping review of quality indicators. Blood Transfusion 2020;18(6), 423. Doi: 10.2450/2020.0082-20

Sanderson, B. J., Field, J. D., Estcourt, L. J., Wood, E. M., & Coiera, E. W. Massive transfusion experience, current practice and decision support: A survey of Australian and New Zealand anaesthetists. Anaesthesia and Intensive Care 2021. Doi: 0310057X20974035.

Sanderson B, Field JD, Kocaballi AB, et al. Multicenter, multidisciplinary user-centered design of a clinical decision-support and simulation system for massive transfusion. Transfusion. 2023;63(5):993-1004. Doi: 10.1111/trf.17315

Last modified: